Despite some advances in treatment modalities, the survival of ovarian cancer has hardly improved for decades and identification of modifiable factors that can improve the prognosis of ovarian cancer patients remains a high priority ([@bib1]).

Several epidemiologic studies suggest improved cancer outcomes with regular aspirin use among patients with clinically manifest cancer, and a number of randomised clinical trials are currently ongoing to evaluate the role of aspirin in the treatment of common cancers, notably colorectal cancer ([@bib6]; [@bib8]). The exact mechanisms behind the antineoplastic effects of aspirin remain to be established ([@bib17]; [@bib19]). For ovarian cancer, some studies in murine models and human cell lines have demonstrated an interaction between platelets and proliferation, angiogenesis, and metastasis of ovarian tumours, suggesting a role for aspirin via the antiplatelet effect ([@bib5]; [@bib3]); however, other mechanisms have also been suggested ([@bib11]; [@bib10]). Only few epidemiologic studies of ovarian cancer patients have evaluated outcomes associated with aspirin use and the results have been too equivocal to allow efficient design of clinical trials ([@bib12]; [@bib13]; [@bib2]; [@bib7]; [@bib21]). A pooled analysis of 12 studies within the Ovarian Cancer Association Consortium (OCAC) reported a neutral association between aspirin use and overall survival among ovarian cancer patients; however, aspirin exposure was self-reported and only prediagnosis use was evaluated ([@bib7]). The influence of postdiagnosis aspirin use, a clinically more relevant exposure, has been explored in only one small cohort study reporting a statistically significant 50% reduction in overall mortality with aspirin use ([@bib2]). This prompted us to conduct a cohort study of postdiagnosis low-dose aspirin use and mortality among ovarian cancer patients in Denmark, using the unique Danish nationwide registries.

Materials and methods
=====================

From the Danish Cancer Registry, we identified all women aged 30--84 years with incident primary epithelial ovarian cancer between 2000 and 2012 and no history of cancer (except non-melanoma skin cancer). Information on filled prescriptions for low-dose aspirin and other drugs, tumour and patient characteristics, comorbid conditions, and mortality outcomes were retrieved from nationwide demographic, prescription, and patient registries, using the unique civil registration number assigned to all Danish residents for linkage. The [Supplementary Material](#sup1){ref-type="supplementary-material"} provides a detailed description of the registries, with codes for ovarian cancer, drug exposure, and covariates.

The study outcomes were ovarian cancer-specific and other-cause mortality. Patients were followed from 1 year after ovarian cancer diagnosis until death, migration, or end of the study (31 December 2013).

We defined postdiagnosis use of low-dose (75--150 mg) aspirin as ⩾1 prescription filled after the ovarian cancer diagnosis. Prediagnosis use of low-dose aspirin was defined as ⩾1 prescription within 5 years before the ovarian cancer diagnosis. In the primary analysis, we assessed postdiagnosis use of low-dose aspirin as a time-varying covariate lagged by 1 year ([@bib4]). Thus, postdiagnosis low-dose aspirin users were regarded as non-users until 1 year after their first prescription.

In secondary analyses, we evaluated the influence of timing of low-dose aspirin use by developing a supplementary time-varying exposure matrix: (1) no pre- or postdiagnosis use (reference group), (2) prediagnosis use only, (3) pre- and postdiagnosis use, and (4) postdiagnosis use only.

In two sensitivity analyses with fixed exposure periods, low-dose aspirin use was assessed from time of diagnosis until the start of follow-up at 1 or 3 years following the ovarian cancer diagnosis, and was considered invariable thereafter ([@bib20]).

We used Cox proportional hazard regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between postdiagnosis low-dose aspirin use and ovarian cancer-specific and other-cause mortality. Minimally adjusted analyses included age at diagnosis, clinical stage, and year of diagnosis. Fully adjusted models further included tumour histology, chemotherapy, highest achieved education, disposable income, marital status, comorbid conditions, and non-aspirin drug use ([Table 1](#tbl1){ref-type="table"} and [Supplementary Material](#sup1){ref-type="supplementary-material"}). The proportional hazards assumption was tested using scaled Schoenfeld residuals. Finally, we evaluated the influence of competing risks as a result of death from other causes using the subdistribution hazards model proposed by Fine and Gray adapted for time-dependent covariates ([@bib9]).

All analyses were performed using the R statistical software version 3.2.3 and the survival package ([@bib14]; [@bib16]). STROBE guidelines were used to outline this study ([@bib22]). The Danish Data Protection Agency and Statistics Denmark's Scientific Board approved the study. According to Danish law, ethical approval is not required for registry-based studies ([@bib18]).

Results
=======

Among 5439 eligible women with a primary diagnosis of epithelial ovarian cancer, 4117 were alive 1 year after the diagnosis and included in our study. During a mean follow-up of 3.6 years (maximum 13 years), 2245 (55%) patients died and of these, 1903 (85%) women died from ovarian cancer. Characteristics of the study population are shown in [Table 1](#tbl1){ref-type="table"}.

In the primary, time-varying analysis, we saw no association between postdiagnosis use of low-dose aspirin and ovarian cancer (HR: 1.02, 95% CI: 0.87--1.20) or other-cause (HR: 1.06, 95% CI: 0.77--1.47) mortality ([Table 2](#tbl2){ref-type="table"}). Further, we observed no substantial variation in HRs according to estimated dose (tablet size), cumulative amount of postdiagnosis low-dose aspirin use, or with timing of use ([Table 2](#tbl2){ref-type="table"}). Stratification according to tumour histology ([Table 3](#tbl3){ref-type="table"}), age at diagnosis, clinical stage, or year of diagnosis ([Online Supplementary eTable 2](#sup1){ref-type="supplementary-material"}) did not materially influence the associations.

We also observed overall neutral associations for ovarian cancer-specific and other-cause mortality in sensitivity analyses, except for an increased HR with short duration of low-dose aspirin use in the 3-year analysis; however, these estimates were based on small numbers ([Supplementary eTable 3](#sup1){ref-type="supplementary-material"}). Finally, analyses accounting for competing risks (Fine and Gray) exhibited results similar to those of the primary analyses (data not shown).

Discussion
==========

Our finding of a null association between use of low-dose aspirin and mortality after ovarian cancer is compatible with the results of the OCAC study based on prediagnosis use, but our results are in contrast to a previous study reporting a substantial reduction in overall mortality among ovarian cancer patients with postdiagnosis aspirin use ([@bib2]). However, besides a small sample size, the latter cohort study was prone to time-related bias which are likely to have influenced the estimates ([@bib4]).

In our study, we evaluated the influence of low-dose aspirin on mortality after ovarian cancer, assuming that one tablet was equivalent to daily use. Higher dosages of aspirin might be required to obtain a beneficial effect on ovarian cancer prognosis; however, this is not readily supported by analyses of various patterns of low-dose aspirin use in our study, or the similar associations for low-dose (\<100 mg) and higher-dose (\>100 mg) aspirin in the OCAC study ([@bib7]). Moreover, for cancer in general, there is no solid evidence that doses of aspirin higher than those used in cardioprotection (75--150 mg) would provide stronger anticancer effects ([@bib6]; [@bib8]).

Among the strengths of our study were the nationwide cohort, large study size, high-quality and continuously updated registry data, and complete follow-up. The use of the Danish Prescription Registry ensured complete assessment of prescription drug use. The study design eliminated recall bias, and minimised selection bias and time-related biases.

A limitation of our study was the lack of data on over-the-counter (OTC) purchases of aspirin. However, in Denmark, most (\>90%) of the total sales of low-dose aspirin are prescribed ([@bib15]), and this proportion may even be higher in cancer patients who are typically under close medical surveillance. High-dose (500 mg) aspirin preparations are mainly sold OTC in Denmark, and thus use of aspirin at this dose may have driven a possible slight inverse association towards the null given that high-dose aspirin is more likely to be used by non-users of low-dose aspirin than among users. However, high-dose aspirin is mainly used for short-term treatment of transient, non-cancer-related pain and therefore OTC use of high-dose aspirin likely resulted in at most minor misclassification of long-term aspirin use. Moreover, the absence of any material differences in associations with increasing dose and cumulative amount of low-dose aspirin indicates that OTC sales of high-dose aspirin likely did not have major impact on our results. Furthermore, in Denmark, regular use of drugs, including high-dose aspirin, is generally prescribed because of at least 50% cost reimbursement and the need for medical surveillance for adverse effects ([@bib15]). In our study population, only five patients filled a minimum of one prescription for high-dose aspirin, thus suggesting that use of aspirin at this dose was indeed only sporadical. Still, although we adjusted for several potential confounding factors, residual confounding could have been introduced by lifestyle factors, such as physical activity, smoking and obesity, or other unmeasured factors potentially associated with both low-dose aspirin use and ovarian cancer mortality.

In conclusion, we found no evidence of reduced mortality among ovarian cancer patients associated with postdiagnosis use of low-dose aspirin.
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###### Characteristics of ovarian cancer patients surviving at least 1 year after the ovarian cancer diagnosis, according to post-diagnosis use of low-dose aspirin within the first year after diagnosis

                                                                                                              **Non-users (*****n*****=3650)**   **Post-diagnosis low-dose aspirin users (*****n*****=467)**
  ------------------------------------------------- --------------------------------------------------------- ---------------------------------- -------------------------------------------------------------
  Prediagnosis low-dose aspirin use                 Use                                                       179 (4.9)                          374 (80.1)
                                                    Non-use                                                   3471 (95.1)                        93 (19.9)
  Year of diagnosis                                 2000--2003                                                1197 (32.8)                        130 (27.8)
                                                    2004--2007                                                1131 (31.0)                        123 (26.3)
                                                    2008--2012                                                1322 (36.2)                        214 (45.8)
  Age at diagnosis                                  Median (IQR)                                              60 (52--68)                        70 (63--76)
  Clinical stage                                    Localised                                                 1470 (40.3)                        171 (36.6)
                                                    Non-localised                                             1913 (52.4)                        247 (52.9)
                                                    Unknown                                                   267 (7.3)                          49 (10.5)
  Tumour histology                                  Serous                                                    2164 (59.3)                        279 (59.7)
                                                    Endometrioid                                              484 (13.3)                         72 (15.4)
                                                    Mucinous                                                  351 (9.6)                          28 (6.0)
                                                    Clear cell                                                204 (5.6)                          20 (4.3)
                                                    Other                                                     447 (12.2)                         68 (14.6)
  Chemotherapy                                      Yes                                                       2814 (77.1)                        366 (78.4)
                                                    No                                                        836 (22.9)                         101 (21.6)
  Highest achieved education                        Basic                                                     99 (2.7)                           11 (2.4)
                                                    Vocational/short                                          2560 (70.1)                        388 (83.1)
                                                    Long/medium                                               898 (24.6)                         54 (11.6)
                                                    Unknown                                                   93 (2.5)                           14 (3.0)
  Disposable income                                 Low                                                       1088 (29.8)                        190 (40.7)
                                                    Medium                                                    1208 (33.1)                        186 (39.8)
                                                    High                                                      1354 (37.1)                        91 (19.5)
  Marital status                                    Divorced                                                  460 (12.6)                         51 (10.9)
                                                    Married                                                   2274 (62.3)                        242 (51.8)
                                                    Unmarried                                                 418 (11.5)                         35 (7.5)
                                                    Widow                                                     498 (13.6)                         139 (29.8)
  Comorbid conditions                               Diabetes mellitus                                         137 (3.8)                          69 (14.8)
                                                    COPD                                                      134 (3.7)                          37 (7.9)
                                                    Ischaemic heart disease                                   113 (3.1)                          137 (29.3)
                                                    Congestive heart disease                                  45 (1.2)                           32 (6.9)
                                                    Cerebrovascular disease                                   107 (2.9)                          85 (18.2)
                                                    Atrial fibrillation                                       92 (2.5)                           50 (10.7)
  Other drug use (⩾1 post-diagnosis prescription)   Non-aspirin NSAIDs                                        1050 (28.8)                        157 (33.6)
                                                    Antiplatelet drugs (other)[a](#t1-fn2){ref-type="fn"}     32 (0.9)                           55 (11.8)
                                                    Anticoagulants (other)[b](#t1-fn3){ref-type="fn"}         227 (6.2)                          38 (8.1)
                                                    Statins                                                   287 (7.9)                          186 (39.8)
                                                    *β*-Blockers                                              300 (8.2)                          166 (35.5)
                                                    Calcium channel blockers                                  301 (8.2)                          125 (26.8)
                                                    ACE inhibitors                                            249 (6.8)                          115 (24.6)
                                                    ARBs                                                      221 (6.1)                          67 (14.3)
                                                    Antihypertensives (other)[c](#t1-fn4){ref-type="fn"}      915 (25.1)                         232 (49.7)
                                                    Cardiovascular drugs (other)[d](#t1-fn5){ref-type="fn"}   83 (2.3)                           79 (16.9)
                                                    Insulin and analogues                                     38 (1.0)                           27 (5.8)
                                                    Metformin                                                 56 (1.5)                           31 (6.6)
                                                    Oral antidiabetics (other)[e](#t1-fn6){ref-type="fn"}     52 (1.4)                           24 (5.1)
                                                    Paracetamol                                               852 (23.3)                         195 (41.8)
                                                    Proton pump inhibitors                                    988 (27.1)                         192 (41.1)
                                                    Bisphosphonates                                           101 (2.8)                          26 (5.6)
                                                    Antihistamines                                            268 (7.3)                          41 (8.8)
                                                    Drugs against COPD                                        40 (1.1)                           15 (3.2)
                                                    High-dose aspirin[f](#t1-fn7){ref-type="fn"}              5 (0)                              0 (0)

Abbreviations: ACE=angiotensin-converting enzyme; ADP=adenosine diphosphate; ARB=angiotensin II receptor blocker; COPD=chronic obstructive pulmonary disease; IQR=interquartile range; NSAIDs=non-steroidal anti-inflammatory drugs.

Dipyridamole and ADP receptor antagonists.

Vitamin K antagonists, heparin group, direct thrombin inhibitors, and direct factor Xa inhibitors.

Antiadrenergic drugs and diuretics.

Cardiac glycosides, antiarrhythmic agents, cardiac stimulants, vasodilators, and prostaglandins.

Sulfonylureas, *α*-glucosidase inhibitors, thiazolinediones, dipeptidyl-peptidase-4 inhibitors, and other blood glucose-lowering drugs.

Not included in multivariable-adjusted analysis due to low numbers.

###### Association between postdiagnosis low-dose aspirin use and ovarian cancer-specific and other-cause mortality, using time-varying analysis

                                                                            **Ovarian cancer-specific mortality**   **Other-cause mortality**                                                                             
  ------------------------------------------------------------------------- --------------------------------------- --------------------------- ------------------- ------------------- ------- ----- ------------------- -------------------
  Non-use                                                                   12 914                                  1661                                 1                   1          12914   272            1                   1
  Post-diagnosis use                                                        1832                                    242                          1.07 (0.93--1.23)   1.02 (0.87--1.20)  1832    70     1.24 (0.93-1.66)    1.06 (0.77--1.47)
  **Dose (tablet size)**                                                                                                                                                                                                  
  75--100 mg                                                                1368                                    179                          1.03 (0.88--1.21)   0.98 (0.82--1.17)  1368    45     1.08 (0.77--1.51)   0.95 (0.66--1.38)
  150 mg                                                                    325                                     52                           1.23 (0.93--1.64)   1.20 (0.90--1.61)  325     14     1.52 (0.86--2.68)   1.31 (0.73--2.37)
  Mixed                                                                     139                                     11                           1.07 (0.58--1.97)   0.87 (0.47--1.63)  139     11     2.28 (1.16--4.48)   1.53 (0.74--3.15)
  **Cumulative amount (tablets)**                                                                                                                                                                                         
  1--365                                                                    620                                     114                          1.12 (0.92--1.37)   1.07 (0.87--1.32)  620     25     1.45 (0.94-2.22)    1.29 (0.83--2.00)
  366--1095                                                                 681                                     78                           0.89 (0.71--1.13)   0.87 (0.67--1.11)  681     23     1.19 (0.76--1.86)   0.99 (0.61--1.60)
  ⩾1096                                                                     531                                     50                           1.34 (0.98--1.84)   1.22 (0.88--1.70)  531     22     1.07 (0.64--1.77)   0.87 (0.50--1.49)
  **Timing[c](#t2-fn4){ref-type="fn"}**                                                                                                                                                                                   
  Never use                                                                 12378                                   1552                                 1                   1          12378   253            1                   1
  Prediagnosis use only                                                     536                                     109                          1.03 (0.84--1.26)   0.92 (0.74--1.13)  536     19     1.11 (0.68--1.80)   0.91 (0.54--1.51)
  Post-diagnosis use only                                                   841                                     74                           1.07 (0.83--1.36)   1.00 (0.77--1.29)  841     26     0.99 (0.63--1.56)   0.89 (0.56--1.42)
  Pre- and postdiagnosis use                                                992                                     168                          1.07 (0.91--1.27)   1.01 (0.84--1.22)  992     44     1.44 (1.02--2.03)   1.18 (0.79--1.75)
  **Prediagnosis cumulative amount (tablets)[d](#t2-fn5){ref-type="fn"}**                                                                                                                                                 
  1--999                                                                    506                                     80                           0.99 (0.79--1.25)   0.95 (0.74--1.22)  506     17     1.15 (0.69--1.91)   1.01 (0.58--1.75)
  ⩾1000                                                                     486                                     88                           1.16 (0.93--1.44)   1.07 (0.84--1.36)  486     27     1.72 (1.12--2.63)   1.34 (0.82--2.17)

Abbreviations: CI=confidence interval; HR=hazard ratio.

Adjusted for age at diagnosis, year of diagnosis, and clinical stage.

Adjusted for age at diagnosis, year of diagnosis, clinical stage, tumour histology, chemotherapy, highest achieved education, disposable income, marital status, use of non-aspirin drugs, and comorbid conditions.

A supplementary exposure matrix including both pre- and postdiagnosis low-dose aspirin use was developed, using four time-varying categories: (1) no pre- or postdiagnosis use ('never use', reference), (2) prediagnosis use only, (3) postdiagnosis use only, and (4) both pre- and postdiagnosis use.

Evaluation according to cumulative number of prediagnosis low-dose aspirin tablets among patients with both pre- and postdiagnosis use, compared with never use.

###### Association between post-diagnosis low-dose aspirin use and ovarian cancer-specific and other-cause mortality, using time-varying analysis and stratified by tumour histology

                                      **Ovarian cancer-specific mortality**   **Other-cause mortality**                                                                             
  -------------- -------------------- --------------------------------------- --------------------------- ------------------- ------------------- ------ ----- -------------------- -------------------
  Serous         Non-use              6643                                    1123                                 1                   1          6643   150            1                    1
                 Post-diagnosis use   917                                     162                          1.04 (0.87--1.24)   0.98 (0.81--1.19)  917    33     1.22 (0.80--1.86)    0.95 (0.61--1.50)
  Endometrioid   Non-use              2209                                    153                                  1                   1          2209   35             1                    1
                 Post-diagnosis use   332                                     27                           1.30 (0.82--2.07)   1.26 (0.79--2.02)  332    9      0.49 (0.19--1.24)    0.50 (0.20--1.30)
  Mucinous       Non-use              1757                                    64                                   1                   1          1757   34             1                    1
                 Post-diagnosis use   238                                     8                            1.06 (0.44--2.56)   0.92 (0.37--2.25)  238    14     1.91 (0.85--4.30)    1.52 (0.66--3.48)
  Clear-cell     Non-use              803                                     71                                   1                   1          803    11             1                    1
                 Post-diagnosis use   151                                     10                           0.68 (0.30--1.55)   0.72 (0.31--1.63)  151    5      2.46 (0.57--10.60)   1.87 (0.45--7.86)
  Other          Non-use              1502                                    250                                  1                   1          1502   42             1                    1
                 Post-diagnosis use   194                                     35                           1.06 (0.70--1.59)   1.02 (0.67--1.54)  194    9      1.43 (0.60--3.42)    1.37 (0.55--3.42)

Abbreviations: CI=confidence interval; HR=hazard ratio.

Adjusted for age at diagnosis, year of diagnosis, and clinical stage.

Adjusted for age at diagnosis, year of diagnosis, clinical stage, chemotherapy, highest achieved education, disposable income, marital status, use of non-aspirin drugs, and comorbid conditions.
